Abstract
Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Medicinal Chemistry
Title: The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers
Volume: 3 Issue: 6
Author(s): Allen B. Reitz, Suneel K. Gupta, Yifang Huang, Michael H. Parker and Richard R. Ryan
Affiliation:
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Abstract: Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Export Options
About this article
Cite this article as:
Reitz B. Allen, Gupta K. Suneel, Huang Yifang, Parker H. Michael and Ryan R. Richard, The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers, Medicinal Chemistry 2007; 3 (6) . https://dx.doi.org/10.2174/157340607782360353
DOI https://dx.doi.org/10.2174/157340607782360353 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol as a Protective Molecule for Neuroinflammation: A Review of Mechanisms
Current Pharmaceutical Biotechnology Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry COX-2 and mPGES in Brain Endothelial Cells: Potential Targets of Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy The Potential Role of Dysfunctions in Neuron-Microglia Communication in the Pathogenesis of Brain Disorders
Current Neuropharmacology Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine Highlights in the Development of New Antiviral Agents
Mini-Reviews in Medicinal Chemistry Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design